Feedback

A universal cannabinoid CB1 and CB2 receptor TR-FRET kinetic ligand-binding assay

Affiliation
Division of Physiology ,Pharmacology & Neuroscience ,School of Life Sciences ,University of Nottingham ,Nottingham ,United Kingdom
Borrega-Roman, Leire;
Affiliation
Division of Physiology ,Pharmacology & Neuroscience ,School of Life Sciences ,University of Nottingham ,Nottingham ,United Kingdom
Hoare, Bradley L.;
Affiliation
Laboratorium für Organische Chemie ,Eidgenössische Technische Hochschule Zürich ,Zürich ,Switzerland
Kosar, Miroslav;
Affiliation
Laboratorium für Organische Chemie ,Eidgenössische Technische Hochschule Zürich ,Zürich ,Switzerland
Sarott, Roman C.;
Affiliation
Laboratorium für Organische Chemie ,Eidgenössische Technische Hochschule Zürich ,Zürich ,Switzerland
Patej, Kacper J.;
Affiliation
Division of Drug Discovery and Safety ,Leiden Academic Center for Drug Research ,Leiden University and Oncode Institute ,Leiden ,Netherlands
Bouma, Jara;
Affiliation
Division of Physiology ,Pharmacology & Neuroscience ,School of Life Sciences ,University of Nottingham ,Nottingham ,United Kingdom
Scott-Dennis, Morgan;
Affiliation
Division of Physiology ,Pharmacology & Neuroscience ,School of Life Sciences ,University of Nottingham ,Nottingham ,United Kingdom
Koers, Eline J.;
Affiliation
Leibniz-Forschungsinstitut für Molekulare Pharmakologie FMP ,Campus BerlinBuch ,Berlin ,Germany
Gazzi, Thais;
Affiliation
Leibniz-Forschungsinstitut für Molekulare Pharmakologie FMP ,Campus BerlinBuch ,Berlin ,Germany
Mach, Leonard;
Affiliation
Department of Pharmacology ,Faculty of Pharmacy ,University of the Basque Country UPV/EHU ,Vitoria-Gasteiz ,Spain
Barrondo, Sergio;
Affiliation
Department of Pharmacology ,Faculty of Pharmacy ,University of the Basque Country UPV/EHU ,Vitoria-Gasteiz ,Spain
Sallés, Joan;
Affiliation
Roche Pharma Research and Early Development ,Roche Innovation Center Basel ,F. Hoffmann-La Roche Ltd. ,Basel ,Switzerland
Guba, Wolfgang;
Affiliation
Roche Pharma Research and Early Development ,Roche Innovation Center Basel ,F. Hoffmann-La Roche Ltd. ,Basel ,Switzerland
Kusznir, Eric;
Affiliation
Leibniz-Forschungsinstitut für Molekulare Pharmakologie FMP ,Campus BerlinBuch ,Berlin ,Germany
Nazaré, Marc;
Affiliation
Roche Pharma Research and Early Development ,Roche Innovation Center Basel ,F. Hoffmann-La Roche Ltd. ,Basel ,Switzerland
Rufer, Arne C.;
Affiliation
Roche Pharma Research and Early Development ,Roche Innovation Center Basel ,F. Hoffmann-La Roche Ltd. ,Basel ,Switzerland
Grether, Uwe;
Affiliation
Division of Drug Discovery and Safety ,Leiden Academic Center for Drug Research ,Leiden University and Oncode Institute ,Leiden ,Netherlands
Heitman, Laura H.;
Affiliation
Laboratorium für Organische Chemie ,Eidgenössische Technische Hochschule Zürich ,Zürich ,Switzerland
Carreira, Erick M.;
Affiliation
Division of Physiology ,Pharmacology & Neuroscience ,School of Life Sciences ,University of Nottingham ,Nottingham ,United Kingdom
Sykes, David A.;
Affiliation
Division of Physiology ,Pharmacology & Neuroscience ,School of Life Sciences ,University of Nottingham ,Nottingham ,United Kingdom
Veprintsev, Dmitry B.

Introduction The kinetics of ligand binding to G protein-coupled receptors (GPCRs) is an important optimization parameter in drug discovery. Traditional radioligand assays are labor-intensive, preventing their application at the early stages of drug discovery. Fluorescence-based assays offer several advantages, including a possibility to develop a homogeneous format, continuous data collection, and higher throughput. This study sought to develop a fluorescence-based binding assay to investigate ligand-binding kinetics at human cannabinoid type 1 and 2 receptors (CB1R and CB2R). Methods We synthesized D77, a novel tracer derived from the non-selective cannabinoid Δ 8 -THC. Using time-resolved Förster resonance energy transfer (TR-FRET), we developed an assay to study ligand-binding kinetics at physiological temperatures. For CB1R, we truncated the first 90 amino acids of its flexible N-terminal domain to reduce the FRET distance between the terbium cryptate (donor) and the fluorescent ligand (acceptor). The full-length CB2R construct was functional without modification due to its shorter N-terminus. The Motulsky–Mahan competition binding model was used to analyze the binding kinetics of the endocannabinoids and several other non-fluorescent ligands. Results The D77 tracer showed nanomolar-range affinity for truncated CB1R (CB1R 91-472 ) and full-length CB2R (CB2R 1–360 ), displaying competitive binding with orthosteric ligands. D77 exhibited rapid dissociation kinetics from both CB1R and CB2R, which were similar to the fastest dissociating reference compounds. This was critical for accurately determining the on- and off-rates of the fastest dissociating compounds. Using D77, we measured the kinetic binding properties of various CB1R and CB2R agonists and antagonists at physiological temperature and sodium ion concentration. Discussion The k on values for molecules binding to CB1R varied by three orders of magnitude, from the slowest (HU308) to the fastest (rimonabant). A strong correlation between k on and affinity was observed for compounds binding to CB1R, indicating that the association rate primarily determines their affinity for CB1R. Unlike CB1R, a stronger correlation was found between the dissociation rate constant k off and the affinity for CB2R, suggesting that both k on and k off dictate the overall affinity for CB2R. Exploring the kinetic parameters of cannabinoid drug candidates could help drug development programs targeting these receptors.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2025 Borrega-Roman, Hoare, Kosar, Sarott, Patej, Bouma, Scott-Dennis, Koers, Gazzi, Mach, Barrondo, Sallés, Guba, Kusznir, Nazaré, Rufer, Grether, Heitman, Carreira, Sykes and Veprintsev.

Use and reproduction: